Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q1 2023 · 10-Q
Revenue$0.00$0.00— vs Q1 2022 Net Income-$5.09M-$5.09MN/M vs Q1 2022 EPS Diluted-$7.98-$7.98N/M vs Q1 2022 Operating Income-$4,580,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 10, 2022 · 41 d after period end